Symic Bio

Symic Biomedical is a biotechnology startup founded in 2012 that focuses on empowering healing from within through innovative matrix regulator therapeutics for fibrosis, oncology, and central nervous system diseases. The company's treatments aim to influence matrix degradation and structure, connecting with damaged matrix targets caused by injury or disease to effectively reduce pathological inflammatory responses. Symic Biomedical's approach holds potential applications in fibrosis, oncology, and central nervous system disorders. The company recently secured a $11.00M Series C investment on 25 April 2019, with backing from Cell Innovation Partners, ReproCELL, and Shinsei Bank. This significant investment speaks to the confidence these industry players have in Symic Biomedical's mission and the promise of its innovative matrix regulator therapeutics. With its focus on critical areas within the healthcare industry, including oncology and central nervous system diseases, Symic Biomedical stands poised to make a meaningful impact in the field of biotechnology and health care.